| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Microbiology, The University of Texas Medical Branch, Galveston, Texas 77550
Mouse immune (IFN-
)2 and virus-type (IFN-
/ß) interferons were used separately and in combination in cloning studies with B-16 melanoma cells. IFN-
was found to be a more potent mediator of the direct anticellular effect of interferon than was IFN-
/ß, as shown not only by a greater sensitivity of B-16 cells to IFN-
but also by a steeper slope of the anticellular sensitivity curve of the IFN-
. The differences in the slopes of the curves defining their anticellular effect appeared to be inherent in the interferons themselves and not due to an inhibitor of interferon, a stimulator of cell growth, or another factor possessing anticellular activity. The results are consistent with the interpretation that IFN-
and IFN-
/ß exert their anticellular effects by different mechanisms. The anticellular activity of interferon against B-16 melanoma replication unit development was potentiated by mixed preparations of IFN-
and IFN-
/ß. The potentiation appeared to be an expression of a property of the interferons themselves. Replication units resistant to the potentiated activity of the interferons were not detected. Potentiation levels were dependent on the concentrations of both IFN-
and IFN-
/ß and continued to increase dramatically as the interferon concentrations increased. Maximum potentiation observed was 214-fold at the highest interferon concentrations used. The data suggest that potentiation is a mutual, synergistic interaction of IFN-
and IFN-
/ß.
1 Supported by USPHS Grant 5R01 CA 26475 awarded by the Department of Health and Human Services, National Cancer Institute.
Received 8/ 3/81. Accepted 11/30/81.
This article has been cited by other articles:
![]() |
A.-S.A. Ismail, C. J. Van Groeningen, A. Hardcastle, Q.-F. Ren, G. W. Aherne, F. Geoffroy, C. J. Allegra, and J. L. Grem. Modulation of Fluorouracil Cytotoxicity by Interferon-alpha and -gamma Mol. Pharmacol., February 1, 1998; 53(2): 252 - 261. [Abstract] [Full Text] |
||||
![]() |
T. C. Merigan Interferon--The First Quarter Century JAMA, November 19, 1982; 248(19): 2513 - 2516. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |